Ulf Wiinberg is Chief Executive Officer of Lundbeck from 1 June 2008.
He was previously with U.S. medical corporation Wyeth for 27 years, most recently as President of Wyeth Europe, Middle East, Africa and Canada with responsibility for Wyeth’s biopharma activities, and as a member of Wyeth's Corporate Management Committee.
Ulf Wiinberg is Chairman of the Board in the British company Avillion and is a board member of EFPIA in Europe, PhRMA in the United States and Alfa Laval in Sweden and serves on the Industrial Policy Committee under the Confederation of Danish Industry (Dansk Industris Erhvervspolitiske Udvalg).
Following his degree in medicine and research fellow positions at Copenhagen hospitals, Anders Gersel Pedersen worked for Eli Lilly for 11 years: 10 of these as a director overseeing worldwide clinical research in oncology. In 2000 he joined Lundbeck as Vice President of International Clinical Research, he was later appointed Executive Vice President of Drug Development and in 2011 appointed responsible for all Research & Development activities at Lundbeck.
He is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. Anders Gersel Pedersen also serves on the Board of Directors at Bavarian Nordic A/S and ALK A/S and is Chairman in Genmab A/S.
After finishing his education, Anders Götzsche joined PriceWaterhouseCoopers in 1991. From 1998 he was a Sales Manager with the SAS Institute until 2001, after which he became Director of Group Accounting and Reporting in Group 4 Falck. From 2005 he held the post of Chief Financial Officer for the Berlingske Officin. He joined Lundbeck in 2007.
Anders Götzsche holds a Master of Science in Accounting from University of Southern Denmark (1991) and he became a state authorized public accountant in 1997.
Anders Götzsche is a member of the board of Veloxis Pharmaceutical A/S.